Among the most expensive therapies are gene therapies that show promise to transform inherited disor...
Read moreThe Federal Joint Committee (G-BA) has set out criteria for ATMPs which are likely to require qualit...
Read moreThe provision of funding for Early Access Programmes is not ubiquitous. We explore which EU5 countri...
Read moreNICE has recommended the first CAR T-cell therapy, Yescarta for the treatment of some lymphomas in a...
Read moreThe economic committee for health products (CEPs) have announced a price reduction of €67 that wil...
Read moreBiopharmas offer significant discounts on their products in China, to try and score spots on the cou...
Read moreJapan’s largest drugmaker Takeda says it aims to seek marketing authorisation for its TAK-755 enzy...
Read moreTwo global pharma companies withdraw from the UK’s Voluntary Scheme for Branded Medicines Pricing ...
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreOur client needed a rapid pricing and market access (P&MA) assessment across the US and EU5 in sever...
Read more